Health-related quality of life in hereditary angioedema patients treated with subcutaneous C1 inhibitor (C1-INH) therapy in Canada
Authors:
- Susan WasermanSWSusan Waserman
- Gina LacuestaGLGina Lacuesta
- Amin S. KananiAKAmin S. Kanani
- Gord L. SussmanGSGord L. Sussman
- Harold KimHKHarold Kim
- Hugo ChapdelaineHCHugo Chapdelaine
- Hadi A. Goubran MessihaHMHadi A. Goubran Messiha
- Chrystyna KalicinskyCKChrystyna Kalicinsky
- Adil AdatiaAAAdil Adatia
- Belinda YapBYBelinda Yap
- Marie-France DansereauMDMarie-France Dansereau
- Nataly TaniosNTNataly Tanios
Open Access
- 8 December 2025
- journal article
- research article
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 21 (1)
Abstract
Background: Hereditary angioedema (HAE) therapies have demonstrated improvements in clinical symptoms and health-related quality of life (HR-QoL) in patients with HAE. Specific causes for improvement in HR-QoL have not been sufficiently explored in Canada. Objective: To understand patient perspectives on the burden of HAE and their experiences taking subcutaneous plasma-derived C1 inhibitor concentrate (SC-pdC1INH), and to investigate changes in HR-QoL domains which include physical, mental, emotional, functional, social, and medical well-being. Methods: A qualitative research design was employed using telephone interviews from May to July 2023 and a quantitative self-administered Angioedema QoL questionnaire (AE-QoL), which has a recall period of 4 weeks. A conceptual map was generated from the interviews that illustrated HR-QoL domains most important to patients. Results: This study included 20 patients (50% female; mean age of 51 years; 85% HAE Type 1/2). Patients reported more controlled HAE since starting SC-pdC1INH, with fewer attacks (85%) and even no/nearly no attacks (60%) in the past year. Patients reported emotional benefits (reduced stress/anxiety regarding potential attacks [75%], and increased confidence in managing HAE [95%]). Positive impacts also included increased productivity/less missed days from work/school (40%) and improved physical ability/well-being (50%). The total mean AE-QoL Score was 34 (range 0–87; SD 24.9), indicating a small effect of HAE on HR-QoL in the 4-week pre-interview period. Conclusion: Overall, patients on long-term prophylaxis with SC-pdC1INH reported improvements in many HR-QoL domains, but most significantly relief of stress and anxiety associated with HAE, and improvement in social and physical well-being.Keywords
Funding Information
- CSL Behring Canada Inc.
This publication has 23 references indexed in Scilit:
- A narrative review of recent literature of the quality of life in hereditary angioedema patientsWorld Allergy Organization Journal, 2023
- Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient ManagementClinical Therapeutics, 2021
- Patient-reported burden of hereditary angioedema: findings from a patient survey in the United StatesAnnals of Allergy, Asthma & Immunology, 2020
- Small Data Challenges of Studying Rare DiseasesJAMA Network Open, 2020
- Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary AngioedemaThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- The Angioedema Quality of Life Questionnaire (AE‐QoL) – assessment of sensitivity to change and minimal clinically important differenceAllergy, 2016
- Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoLThe Journal of Allergy and Clinical Immunology: In Practice, 2016
- Development and construct validation of the angioedema quality of life questionnaireAllergy, 2012
- Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research projectHealth and Quality of Life Outcomes, 2012
- Hereditary AngioedemaNew England Journal of Medicine, 1996